The cellular neurobiology of depression
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Major depressive disorders, long considered to be of neurochemical origin, have recently been associated with impairments in signaling pathways that regulate neuroplasticity and cell survival. Agents designed to directly target molecules in these pathways may hold promise as new therapeutics for depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Antidepressant therapies may compensate for this dysfunction by modulating the pathological limbic activity that putatively mediates depressive symptoms (Drevets et al, 2002a), or by enhancing the expression of neurotrophic factors that protect medial network function from the effects of repeated stress (Manji et al, 2001).”
From Neurocircuitry of Mood Disorders (2010) · cites this paper as Manji et al, 2001
In the citing paper
“Somatic antidepressant therapies may compensate for this dysfunction by modulating the pathological limbic activity which putatively mediates depressive symptoms (Drevets et al. 2002a) and the expression of neurotrophic/neuroprotective factors that preserve the function of the MPFC (Manji et al. 2001).”
From Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression (2008) · cites this paper as Manji et al. 2001
In the citing paper
“Depression is often associated with elevated HPA axis activity and increased levels of glucocorticoids, as well as disruption of negative feedback mechanisms21–23.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [22]
Citations
Cites
Neurogenesis in the adult human hippocampus
Eriksson, P. S., Perfilieva, E., Björk-Eriksson, T., Alborn, A.-M., Nordborg, C., Peterson, D. A., & Gage, F. H. (1998) · Nature Medicine · doi:10.1038/3305 · Cited by 6,369 · cited 1×
“However, the demonstration that neurogenesis occurs in the adult human brain into senescenc”
BackgroundThe Bcl-2 Protein Family: Arbiters of Cell Survival
Adams, J. M., & Cory, S. (1998) · Science · doi:10.1126/science.281.5381.1322 · Cited by 5,332 · cited 1×
“Modest changes in this signaling cascade or in the levels of the Bcl-2 family of proteins (potentially due to genetic, illness or insult-related factors) could therefore profoundly affect cellular viabilit”
BackgroundGlobal mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07495-8 · Cited by 4,492 · cited 1×
“It is thus not altogether surprising that the Global Burden of Disease Study has identified MDDs among the leading causes of disability worldwide, and as illnesses likely to represent an increasingly greater health, societal and economic problem in the coming year”
BackgroundAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“Current research is examining the potential efficacy of antagonists of corticotropin-releasing factor (CRF), antiglucocorticoids and direct and indirect glutamate antagonist”
BackgroundSelf-citationChronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111 · cited 1×
“These studies demonstrate that chronic administration of different classes of antidepressants increases the proliferation and survival of new neuron”
BackgroundPsychopharmacology: The Fourth Generation of Progress
Bloom, F. E., & Kupfer, D. J. (1995) · Medical Entomology and Zoology · Cited by 2,985
A molecular mechanism for the effect of lithium on development.
Klein, P. S., & Melton, D. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8455 · Cited by 2,301 · cited 1×
“Moreover, lithium also inhibits the activity of glycogen synthase kinase 3β (GSK-3β”
BackgroundThe Corticosteroid Receptor Hypothesis of Depression
Holsboer, F. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00159-7 · Cited by 2,181
A molecular and cellular theory of depression
Duman, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190015002 · Cited by 2,129 · cited 1×
“have demonstrated that an important pathway involved in cell survival and plasticity, the cAMP–CREB cascade, is up-regulated by antidepressant treatmen”
BackgroundTHE EFFECTS OF STRESSFUL LIFE EVENTS ON DEPRESSION
Kessler, R. C. (1997) · Annual Review of Psychology · doi:10.1146/annurev.psych.48.1.191 · Cited by 2,111 · cited 1×
“Thus, although MDDs undoubtedly have a strong genetic basis, severe stressors have been associated with a substantial increase in risk for the onset of MDDs in susceptible individuals ( Table 3”
Background
Research works printed but not linked: 4
- Garlow, S.J., Musselman, D.L. & Nemeroff C.B. The Neurochemistry of Mood Disorders clinical studies. in Neurobiology of Mental Illness. (eds. Charney, D.S., Nester, E.J. & Bunney, B.S.) 348–364 (Oxford Press, New York, 1999).
- Drevets, W.C., Gadde, K. & Krishnan, R. Neuroimaging studies of depression. in Neurobiology of Mental Illness. (eds. Charney, D.S., Nester, E.J. & Bunney, B.S.) 394–418 (Oxford Press, New York, 1999).
- LeDoux, J.E. Emotion. in Handbook of Physiology—The Nervous System, Vol. V. (eds. Mills, J., Mountcastle, V.B., Plum, F. & Geiger, S.R.) 373–417 (Williams & Wilkins, Baltimore, 1987).
- Manji, H.K. et al. Regulation of signal transduction pathways by mood stabilizing agents: Implications for the pathophysiology and treatment of bipolar affective disorder. in Bipolar Medications: Mechanisms of Action. (eds. Manji, H.K., Bowden, C.L. & Belmaker, R.H.) 129–177 (American Psychiatric Press, Washington, DC, 2000).
Cited by
Items 101–200 of 1,000
Svenningsson, P., Bateup, H., Qi, H., Takamiya, K., Huganir, R. L., Spedding, M., Roth, B. L., McEwen, B. S., & Greengard, P. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05952.x · Cited by 289
“…phosphorylation in frontal cortex and hippocampus Functional neuroimaging studies have shown that there is an altered activity in prefrontal cortex and hippocampus in depressed individuals that is, at least partly, reversible by antidepressant regimens (Manji et al., 2001; Berton & Nestler, 2006).”
BackgroundInfluentialNeurogenesis and affective disorders
Samuels, B. A., & Hen, R. (2011) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07614.x · Cited by 290
“Together, these brain regions operate a series of highly interacting circuits involved in depression (Manji et al., 2001; Nestler et al., 2002).”
BackgroundSegman, R. H., Shefi, N., Goltser-Dubner, T., Friedman, N., Kaminski, N., & Shalev, A. Y. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001636 · Cited by 281
Horn (2010) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2010.00033 · Cited by 276
Wang, J., Hodes, G. E., Zhang, H., Zhang, S., Zhao, W., Golden, S. A., Bi, W., Menard, C., Kana, V., Leboeuf, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02794-5 · Cited by 274
Alterations of neuroplasticity in depression: the hippocampus and beyond
Fuchs, E., Czéh, B., Kole, M. H. P., Michaelis, T., & Lucassen, P. J. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.09.002 · Cited by 269
“for example, while—with further progression of the syndrome—hippocampal atrophy also occurs (Manji et al., 2001; Manji and Duman, 2001; Sheline et al., 2003).”
BackgroundLi, S., Wang, C., Wang, M., Li, W., Matsumoto, K., & Tang, Y. (2007) · Life Sciences · doi:10.1016/j.lfs.2006.12.027 · Cited by 263
“All these changes could lead to reduction of hippocampal volume and vulnerability to subsequent episodes of depression as a result of decreased neurogenesis, increased remodeling of dendrites, and loss of glial cells (for review see Manji et al., 2001; Nestler et al., 2002a,b; Coyle and Duman, 2003).”
BackgroundGenetic variation in cortico-amygdala serotonin function and risk for stress-related disease
Holmes, A. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.006 · Cited by 264
“The time lag between drug action and clinical efficacy alone demonstrates that SERT blockade is not in and of itself sufficient to alleviate stress-related symptoms and likely represents the initial stage upstream of a complex process eventually leading to therapeutic outcome (Blier and de Montigny, 1994; Duman et al.…”
BackgroundMasi, G., & Brovedani, P. (2011) · CNS Drugs · doi:10.2165/11595900-000000000-00000 · Cited by 260
Prenatal maternal depression associates with microstructure of right amygdala in neonates at birth.
Rifkin-Graboi, A., Bai, J., Chen, H., Hameed, W. B., Sim, L. W., Tint, M. T., Leutscher-Broekman, B., Chong, Y.-S., Gluckman, P. D., Fortier, M. V., et al. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.06.019 · Cited by 258
Consensus statement: The evaluation and treatment of people with epilepsy and affective disorders
Barry, J. J., Ettinger, A. B., Friel, P., Gilliam, F. G., Harden, C. L., Hermann, B., Kanner, A. M., Caplan, R., Plioplys, S., Salpekar, J., et al. (2008) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2008.04.005 · Cited by 249
“BAD with an AD without a mood-stabilizing agent runs the risk of pushing the patient into the manic phase of the illness and changing the appearance of the disorder, that is, cycle acceleration [343].”
BackgroundConsensus paper of the WFSBP Task Force on Biological Markers: Biological Markers in Depression
Mössner, R., Mikova, O., Koutsilieri, E., Saoud, M., Ehlis, A.-C., Müller, N., Fallgatter, A. J., & Riederer, P. (2007) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701263303 · Cited by 254
“…are consistently increased in the amygdala, orbital cortex, and medial thalamus, and decreased in the dorsomedial/dorsal anterolateral PFC and anterior cingulate cortex ventral to the genu of the corpus callosum (subgenual PFC) relative to healthy controls (Drevets 2001; Manji et al. 2001).”
BackgroundQi, X., Lin, W., Li, J., Li, H., Wang, W., Wang, D., & Sun, M. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.05.003 · Cited by 249
“Novel theories propose that signal pathway related to synaptic plasticity may be the mechanism of antidepressant action and the pathophysiology of depression (Einat et al., 2003; Malberg et al., 2000; Manji et al., 2001).”
Fuxe, K., Dahlström, A., Höistad, M., Marcellino, D., Jansson, A., Rivera, A., Diaz-Cabiale, Z., Jacobsen, K., Tinner-Staines, B., Hagman, B., et al. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.02.009 · Cited by 250
“…reuptake inhibitors, or tricyclic antidepressants (see Fuxe et al., 1983d; Duman et al., 1997; Skolnick, 1999; Nestler et al., 2002; Manji et al., 2001; Nemeroff, 1998), that in turn lead to an increase of extracellularmonoamines (Iversen, 2000; Taylor et al., 2005; Schloss and…”
BackgroundInfluentialHashimoto, R., Numakawa, T., Ohnishi, T., Kumamaru, E., Yagasaki, Y., Ishimoto, T., Mori, T., Nemoto, K., Adachi, N., Izumi, A., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl244 · Cited by 248
Neurotrophic effects of antidepressant drugs
CASTREN, E. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2003.10.004 · Cited by 244
A psychoneuroimmunological review on cytokines involved in antidepressant treatment response
Janssen, D. G. A., Caniato, R. N., Verster, J. C., & Baune, B. T. (2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1103 · Cited by 240
“The CREB protein has been shown to promote brain derived neurotrophic factor (BDNF) expression (Manji et al., 2001).”
BackgroundEffects of mood stabilizers on hippocampus BDNF levels in an animal model of mania
Frey, B. N., Andreazza, A. C., Ceresér, K. M. M., Martins, M. R., Valvassori, S. S., Réus, G. Z., Quevedo, J., & Kapczinski, F. (2006) · Life Sciences · doi:10.1016/j.lfs.2006.01.002 · Cited by 239
A role for AMPA receptors in mood disorders
Alt, A., Nisenbaum, E. S., Bleakman, D., & Witkin, J. M. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.022 · Cited by 238
Jeon, Y. H., Heo, Y. S., Kim, C. M., Hyun, Y. L., Lee, T. G., Ro, S., & Cho, J. M. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-4533-5 · Cited by 232
Leng, L., Zhuang, K., Liu, Z., Huang, C., Gao, Y., Chen, G., Lin, H., Hu, Y., Wu, D., Shi, M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.08.031 · Cited by 236
“MDD was initially thought to be primarily triggered through neuronal dysfunction (Manji et al., 2001).”
Diz-Chaves, Y., Pernía, O., Carrero, P., & Garcia-Segura, L. M. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-71 · Cited by 230
“In turn, decreased hippocampal neurogenesis related to stress-induced increases in plasma glucocorticoids may be involved in mediating depressive affect [46,47].”
BackgroundAntidepressants act by inducing autophagy controlled by sphingomyelin–ceramide
Gulbins, A., Schumacher, F., Becker, K. A., Wilker, B., Soddemann, M., Boldrin, F., Müller, C. P., Edwards, M. J., Goodman, M., Caldwell, C. C., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0090-9 · Cited by 230
Vollmayr, B., Simonis, C., Weber, S., Gass, P., & Henn, F. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00527-4 · Cited by 229
Svenningsson, P., Tzavara, E. T., Witkin, J. M., Fienberg, A. A., Nomikos, G. G., & Greengard, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052712799 · Cited by 230
Zhang, H. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00344-5 · Cited by 229
Integrated Neurobiology of Bipolar Disorder
Maletic, V., & Raison, C. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00098 · Cited by 226
“Together with the ACC and amygdala, the vmPFC may belong to an integrative network involved in processing emotionally relevant information, which coordinates autonomic and endocrine responses and influences behavior (100).”
MethodChiu, C.-T., & Chuang, D.-M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.07.006 · Cited by 229
Sex differences in antidepressant efficacy
LeGates, T. A., Kvarta, M. D., & Thompson, S. M. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-018-0156-z · Cited by 230
An astroglial basis of major depressive disorder? An overview
Wang, Q., Jie, W., Liu, J., Yang, J., & Gao, T. (2017) · Glia · doi:10.1002/glia.23143 · Cited by 222
Novel Drugs and Therapeutic Targets for Severe Mood Disorders
Mathew, S. J., Manji, H. K., & Charney, D. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301652 · Cited by 223
Self-citationLinkenkaer-Hansen, K., Monto, S., Rytsälä, H., Suominen, K., Isometsä, E., & Kähkönen, S. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3244-05.2005 · Cited by 223
“The depressive disorder has been implicated with neuronal atrophy in the hippocampus (Manji et al., 2001; MacQueen et al., 2003; Campbell et al., 2004), of which the theta oscillation is a major operational mode (Buzsáki, 2002).”
Serotonin and emotional processing: does it help explain antidepressant drug action?
Harmer, C. J. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.036 · Cited by 219
Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.010 · Cited by 219
Levkovitz, Y., Harel, E. V., Roth, Y., Braw, Y., Most, D., Katz, L. N., Sheer, A., Gersner, R., & Zangen, A. (2009) · Brain Stimulation · doi:10.1016/j.brs.2009.08.002 · Cited by 217
A possible role of neuropeptide Y in depression and stress
Morales-Medina, J. C., Dumont, Y., & Quirion, R. (2010) · Brain Research · doi:10.1016/j.brainres.2009.09.077 · Cited by 218
“of monoaminergic systems, and genetic factors have been studied to elucidate depressive-related behaviors (Duman, 2004; Manji et al., 2001; Nestler et al., 2002; Sahay and Hen, 2007).”
Leng, Y., Liang, M.-H., Ren, M., Marinova, Z., Leeds, P., & Chuang, D.-M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5467-07.2008 · Cited by 214
“…most likely through GSK-3 inhibition, enhance cellular resilience and plasticity and, in turn, contribute to their clinical efficacy (for review, see Manji et al., 2001; Bachmann et al., 2005), although additional longitudinal clinical studies are required to firmly establish this linkage.”
BackgroundSinnegger-Brauns, M. J., Hetzenauer, A., Huber, I. G., Renström, E., Wietzorrek, G., Berjukov, S., Cavalli, M., Walter, D., Koschak, A., Waldschütz, R., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420208 · Cited by 215
“2DHP brains, this animal model represents a useful and novel tool to further study neuronal circuits underlying depression-like behavior (37).”
MethodFeng, J., Cai, X., Zhao, J., & Yan, Z. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-17-06502.2001 · Cited by 212
Brain-derived neurotrophic factor (BDNF) changes in the serum of depressed women
Aydemir, C., Yalcin, E. S., Aksaray, S., Kisa, C., Yildirim, S. G., Uzbay, T., & Goka, E. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.03.025 · Cited by 211
“Depressed patients exhibit pathological changes in particular brain areas, including limbic (hippocampus and amygdala) and cortical brain regions (Bremner et al., 2000; Mervaala et al., 2000; Manji et al., 2001; Drevetz et al., 1997).”
BackgroundKhawaja, X., Xu, J., Liang, J., & Barrett, J. E. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.10869 · Cited by 205
“…balance between neurotransmitter and/or hormonal levels and cellular signaling processes become perturbed in the central nervous system (CNS) due to genetic and nongenetic alterations, which may cause or result in structural changes in the brain (Manji et al., 2001; Nestler et al., 2002).”
BackgroundSavitz, J., Drevets, W. C., Wurfel, B. E., Ford, B. N., Bellgowan, P. S. F., Victor, T. A., Bodurka, J., Teague, T. K., & Dantzer, R. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.02.007 · Cited by 209
“Mood disorders are increasingly conceptualized as neuropathological conditions characterized by reductions in gray matter volume, dendritic atrophy and/or glial cell loss (Manji et al., 2001; Savitz et al., 2014b).”
BackgroundSelf-citationKozisek, M. E., Middlemas, D., & Bylund, D. B. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.07.001 · Cited by 205
Improving and Accelerating Drug Development for Nervous System Disorders
Pankevich, D. E., Altevogt, B. M., Dunlop, J., Gage, F. H., & Hyman, S. E. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.007 · Cited by 206
Lucassen, P. J., Fuchs, E., & Czéh, B. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.12.014 · Cited by 201
The Antiapoptotic Actions of Mood Stabilizers: Molecular Mechanisms and Therapeutic Potentials
Chuang, D. M. (2005) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2005.tb00026.x · Cited by 217
McIntyre, R. S., Soczynska, J. K., Konarski, J. Z., & Kennedy, S. H. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.1.157 · Cited by 200
“A testable hypothesis is that antidepressants normalise many indices of metabolism via their effects on the HPA axis [4,44-49].”
BackgroundDepression‐resistant endophenotype in mice overexpressing cannabinoid CB 2 receptors
García‐Gutiérrez, M., Pérez‐Ortiz, J., Gutiérrez‐Adán, A., & Manzanares, J. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00819.x · Cited by 196
“Exposure to CMS decreased neurogenesis and produced alterations in the dendrite remodelling process in the hippocampus (Manji et al., 2001; Nestler et al., 2002a,b; Coyle and Duman, 2003).”
Surget, A., Wang, Y., Leman, S., Ibarguen-Vargas, Y., Edgar, N., Griebel, G., Belzung, C., & Sibille, E. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.76 · Cited by 194
Patterns of gene expression in the limbic system of suicides with and without major depression
Sequeira, A., Klempan, T., Canetti, L., ffrench-Mullen, J., Benkelfat, C., Rouleau, G. A., & Turecki, G. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001969 · Cited by 197
Identifying Functional Neuroimaging Biomarkers of Bipolar Disorder: Toward DSM-V
Phillips, M. L., & Vieta, E. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm060 · Cited by 196
“upon regional structural volumes remain unclear.(128,129) The effect of medication upon neural responses during task performance in bipolar populations therefore requires further study.”
BackgroundAgmatine produces antidepressant-like effects in two models of depression in mice
Zomkowski, A. D. E., Hammes, L., Lin, J., Calixto, J. B., Santos, A. R. S., & Rodrigues, A. L. S. (2002) · Neuroreport · doi:10.1097/00001756-200203250-00005 · Cited by 192
Neuronal network plasticity and recovery from depression
Castrén, E. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1 · Cited by 190
Mice selected for high versus low stress reactivity: A new animal model for affective disorders
Touma, C., Bunck, M., Glasl, L., Nussbaumer, M., Palme, R., Stein, H., Wolferstätter, M., Zeh, R., Zimbelmann, M., Holsboer, F., et al. (2008) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2008.03.013 · Cited by 190
“Although some advances unraveling the genetic underpinnings and cellular neurobiology of MD could be made (Manji et al., 2001; Nestler et al., 2002; de Kloet et al., 2005; Levinson, 2006), the etiology, risk factors and underlying mechanisms (including genetic predisposition) of affective disorders…”
BackgroundThe Neurobiology of Depression: an Integrated Overview from Biological Theories to Clinical Evidence
Ferrari, F., & Villa, R. F. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0032-y · Cited by 186
“Apart from these preclinical findings, also neuroimaging studies in depressed patients have demonstrated selective structural changes across various limbic and non-limbic regions: in prefrontal and cingulate cortex, both metabolism and volume are reduced, while hippocampal atrophy occurs with further syndrome progress…”
BackgroundPrenatal stress in rats predicts immobility behavior in the forced swim test
Morley-Fletcher, S., Darnaudery, M., Koehl, M., Casolini, P., Van Reeth, O., & Maccari, S. (2003) · Brain Research · doi:10.1016/s0006-8993(03)03293-1 · Cited by 185
Role of voltage-gated L-type Ca2+ channel isoforms for brain function
Striessnig, J., Koschak, A., Sinnegger-Brauns, M. J., Hetzenauer, A., Nguyen, N. K., Busquet, P., Pelster, G., & Singewald, N. (2006) · Biochemical Society Transactions · doi:10.1042/bst0340903 · Cited by 185
Kole, M. H. P., Swan, L., & Fuchs, E. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02136.x · Cited by 181
“…or gene ã 2002 Federation of European Neuroscience Societies, European Journal of Neuroscience, 16, 807±816 expression (Thome et al., 2000; reviewed by Manji et al., 2001 and Popoli et al., 2001), that all might be critically important to an ultimate improvement in the symptoms of mood disorders.”
BackgroundLu, D.-Y., Tsao, Y.-Y., Leung, Y.-M., & Su, K.-P. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.98 · Cited by 179
“…traditional antidepressants (eg, specific serotonin reuptake inhibitors and TCAs; Charney and Manji, 2004; Duman et al, 1999, 2000; Li et al, 2008a; Manji et al, 2001; Mercier et al, 2004) and off-label agents used for depression treatment (eg, lithium, valproate, omega-3 PUFAs, and atypical…”
Yoshimura, R., Mitoma, M., Sugita, A., Hori, H., Okamoto, T., Umene, W., Ueda, N., & Nakamura, J. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.03.001 · Cited by 178
“Depressed patients exhibit pathological changes in particular brain areas, including the limbic (hippocampus and amygdale) and cortical brain regions (Bremner et al., 1995; Mervaala et al., 2000; Manji et al., 2001; Drevetz et al., 1997).”
BackgroundHirvonen, J., Karlsson, H., Kajander, J., Lepola, A., Markkula, J., Rasi-Hakala, H., Någren, K., Salminen, J. K., & Hietala, J. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008140 · Cited by 180
“, 2005), and they also contribute to hippocampal neurogenesis, a neurobiological substrate for the antidepressant effect (Berton and Nestler, 2006 ; Manji et al., 2001).”
BackgroundMAP Kinase Activation by Fluoxetine and Its Relation to Gene Expression in Cultured Rat Astrocytes
Mercier, G., Lennon, A. M., Renouf, B., Dessouroux, A., Ramaugé, M., Courtin, F., & Pierre, M. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:24:2:207 · Cited by 176
“Suicide is estimated to be the cause of death in up to approx 15% of individuals with major depressive disorders ( Manji et al., 2001 ).”
BackgroundTrends in the Development of New Antidepressants. Is there a Light at the End of the Tunnel?
Pacher, P., & Kecskemeti, V. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043455594 · Cited by 175
Pandey, S. C., Zhang, H., Roy, A., & Misra, K. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4988-05.2006 · Cited by 174
“The role of BDNF has been implicated in several neurological and psychiatric conditions, such as learning and memory, depression , stress, and drug addiction (Siuciak et al., 1997; Horger et al., 1999; Manji et al., 2001; Poo, 2001; Nestler et al., 2002; Shirayama et al., 2002; Duman, 2004).”
Convergent molecular, cellular, and cortical neuroimaging signatures of major depressive disorder
Anderson, K. M., Collins, M. A., Kong, R., Fang, K., Li, J., He, T., Chekroud, A. M., Yeo, B. T. T., & Holmes, A. J. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2008004117 · Cited by 172
“Given that the pathophysiology of depression is complex and involves interactions among diverse cell classes (25), it is important to characterize the cell transcriptional correlates of depression imaging phenotypes.”
BackgroundDepression research: where are we now?
Lee, S., Jeong, J., Kwak, Y., & Park, S. K. (2010) · Molecular Brain · doi:10.1186/1756-6606-3-8 · Cited by 170
“[5-7].”
Major Depression: One Brain, One Disease, One Set of Intertwined Processes
Filatova, E. V., Shadrina, M. I., & Slominsky, P. A. (2021) · Cells · doi:10.3390/cells10061283 · Cited by 160
Kosten, T. A., Galloway, M. P., Duman, R. S., Russell, D. S., & D'Sa, C. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301527 · Cited by 165
“These include CREB, BDNF, and MAP kinases and suggest that ADTs mediate their delayed long-term beneficial effects via neurotrophic and cell survival effects (Manji et al, 2001).”
BackgroundLithium and GSK3-β Promoter Gene Variants Influence White Matter Microstructure in Bipolar Disorder
Benedetti, F., Bollettini, I., Barberi, I., Radaelli, D., Poletti, S., Locatelli, C., Pirovano, A., Lorenzi, C., Falini, A., Colombo, C., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.172 · Cited by 163
“This glial reduction in mood disorders (Manji et al, 2001), paralleled by in vivo changes of DTI measures (Benedetti et al, 2011c) and brain WM volumes, has been associated with the genetic risks to develop BD (van der Schot et al, 2009): GSK3-b inhibition by lithium could act as a protective…”
BackgroundZARATE, C. A., DU, J., QUIROZ, J., GRAY, N. A., DENICOFF, K. D., SINGH, J., CHARNEY, D. S., & MANJI, H. K. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.017 · Cited by 164
Self-citationPKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers
Manji, H. K., & Chen, G. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001018 · Cited by 165
Self-citationFuchs, E., & Flügge, G. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00795-5 · Cited by 188
Tryptophan depletion decreases the recognition of fear in female volunteers
Harmer, C. J., Rogers, R. D., Tunbridge, E., Cowen, P. J., & Goodwin, G. M. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1401-6 · Cited by 163
“Such effects could result from specific changes within the serotonin system (such as desensitization of 5HT2 receptors) or through more distal effects on other neurochemical or neural systems, including changes in intracellular signalling (Manji et al. 2001).”
BackgroundInfluentialLithium: Potential Therapeutics Against Acute Brain Injuries and Chronic Neurodegenerative Diseases
Wada, A., Yokoo, H., Yanagita, T., & Kobayashi, H. (2005) · Journal of Pharmacological Sciences · doi:10.1254/jphs.crj05009x · Cited by 161
Hu, Y., & Russek, S. J. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05237.x · Cited by 161
Activation of Erk and JNK MAPK pathways by acute swim stress in rat brain regions
Shen, C.-P., Tsimberg, Y., Salvadore, C., & Meller, E. (2004) · BMC Neuroscience · doi:10.1186/1471-2202-5-36 · Cited by 163
“It is therefore not unreasonable to speculate that these signal transduction pathways may also be involved in the neuronal plasticity that is presumed to underlie aberrant brain function [9].”
Backgroundvan der Hart, M. G. C., Czéh, B., de Biurrun, G., Michaelis, T., Watanabe, T., Natt, O., Frahm, J., & Fuchs, E. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001130 · Cited by 158
Nicotine exposure during adolescence induces a depression-like state in adulthood
Iñiguez, S. D., Warren, B. L., Parise, E. M., Alcantara, L. F., Schuh, B., Maffeo, M. L., Manojlovic, Z., & Bolaños-Guzmán, C. A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.220 · Cited by 157
“Given that depression is associated with impaired functioning of these systems (Krishnan and Nestler, 2008b; Manji et al, 2001; Nestler et al, 2006), it is conceivable that these drugs enhance serotonin and dopamine transmission in mesolimbic brain regions to reverse depression-like behaviors…”
Silva, R., Mesquita, A. R., Bessa, J. M., Sousa, J. C., Sotiropoulos, I., Leão, P., Almeida, O. F. X., & Sousa, N. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.12.026 · Cited by 171
Du, J., Gray, N. A., Falke, C. A., Chen, W., Yuan, P., Szabo, S. T., Einat, H., & Manji, H. K. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1258-04.2004 · Cited by 157
“These observations have raised the possibility that effective treatments may exert effects on systems known to play critical roles in neuronal plasticity, such as the glutamatergic system (Manji and Lenox, 2000; Manji et al., 2001; D’Sa and Duman, 2002; Nestler et al., 2002a; Young, 2002).”
BackgroundInfluentialSelf-citationBranchi, I. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.08.011 · Cited by 156
“The findings showing that neural plasticity is, on the one hand, significantly reduced in depressed patients and, on the other hand, enhanced by antidepressant drugs suggest that an impairment in neural plasticity plays a role in determining vulnerability to depression (Duman et al., 2000; Manji et al., 2001; Fuchs et…”
BackgroundKappa-opioid ligands in the study and treatment of mood disorders
Carlezon, W. A., Béguin, C., Knoll, A. T., & Cohen, B. M. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.05.008 · Cited by 156
“Virtually all existing medications for psychiatric disorders are based on serendipitous discoveries made decades ago (Ressler and Nemeroff, 2000; Manji et al., 2001; Nestler et al., 2002; Nestler and Carlezon, 2006).”
BackgroundHsiung, S., Adlersberg, M., Arango, V., Mann, J. J., Tamir, H., & Liu, K. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01987.x · Cited by 158
“Recent hypo- theses of the pathology of mood disorders and antidepressant action emphasize the modulation of neoplasticity and cellular viability (Duman et al. 1997; Manji et al. 2001).”
BackgroundMerali, Z., Kent, P., Du, L., Hrdina, P. D., Palkovits, M., Faludi, G., Poulter, M. O., Bédard, T., & Anisman, H. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.08.008 · Cited by 174
Naert, G., IXART, G., Maurice, T., Tapia‐Arancibia, L., & Givalois, L. (2010) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2010.08.006 · Cited by 174
Cellular Plasticity Cascades: Genes-To-Behavior Pathways in Animal Models of Bipolar Disorder
Einat, H., & Manji, H. K. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.11.004 · Cited by 166
Self-citationNeuroplasticity: from MRI to depressive symptoms
Fossati, P., Radtchenko, A., & Boyer, P. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.09.001 · Cited by 187
Chen, F., Madsen, T. M., Wegener, G., & Nyengaard, J. R. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.12.007 · Cited by 165
“Based on these findings, the neuronal plasticity hypothesis suggests that depressive disorders may be related to impairments of structural plasticity and neural cellular resilience in hippocampus and selected brain regions (Manji et al., 2001; Nestler et al., 2002; Duman, 2004).”
Qi, X., Lin, W., Li, J., Pan, Y., & Wang, W. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.08.035 · Cited by 171
Lopresti, A. L., Hood, S. D., & Drummond, P. D. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112458732 · Cited by 151
“…in neurodegeneration, apoptosis, reduced neurogenesis and neuronal plasticity; and mitochondrial disturbances in the form of increased damage to mitochondria and mitochondrial DNA, and lowered ATP production (Manji et al., 2001; Maes et al., 2009c; Raison and Miller, 2011; Leonard and Maes, 2012).”
BackgroundLi, Y.-F. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107494 · Cited by 170
Wegener, G., Volke, V., Harvey, B. H., & Rosenberg, R. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03738-1 · Cited by 160
CREB, neurogenesis and depression
Gass, P., & Riva, M. A. (2007) · BioEssays · doi:10.1002/bies.20658 · Cited by 150
Is acupuncture beneficial in depression: A meta-analysis of 8 randomized controlled trials?
Wang, H., Qi, H. Y., Wang, B.-S., Cui, Y., Zhu, L., Rong, Z., & Chen, H. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.04.020 · Cited by 152
Lu, M., & Ueno, S. (2017) · PLOS ONE · doi:10.1371/journal.pone.0178422 · Cited by 146
Bachmann, R. F., Schloesser, R. J., Gould, T. D., & Manji, H. K. (2005) · Molecular Neurobiology · doi:10.1385/mn:32:2:173 · Cited by 163
Self-citationThe role of glutamate on the action of antidepressants
Hashimoto, K. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.06.013 · Cited by 170
“However, there are limitations to the monoamine hypothesis as it relates to MDD (Manji et al., 2001; Sanacora et al., 2008; Sen and Sanacora, 2008; Hashimoto, 2009a; Skolnick et al., 2009; Tanti and Belzung, 2010).”
BackgroundPouladi, M. A., Graham, R. K., Karasinska, J. M., Xie, Y., Santos, R. D., Petersen, A., & Hayden, M. R. (2008) · Brain · doi:10.1093/brain/awp006 · Cited by 145
“Increasing evidence points to alterations in neuronal plasticity and the consequent disruption in neural circuitry and gene expression as key mechanisms underlying major depressive disorders (Manji et al., 2001; McClung and Nestler, 2008; Pittenger and Duman, 2008).”
BackgroundCai, H. X., Jin, Y., Liu, S., Zhang, Q., Zhang, L., Cheung, T. C. C., Balbuena, L., & Xiang, Y. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.05.115 · Cited by 169
Fuchs, E. (2005) · CNS Spectrums · doi:10.1017/s1092852900010038 · Cited by 147
Metadata
- Authors
- Manji, H. K., Drevets, W. C., & Charney, D. S.
- Affiliations
- National Institutes of Health (US)
- National Institute of Mental Health (US)
- Corresponding author
- Manji, Husseini K.
- Venue
- Nature Medicine
- Published
- 2001-05
- Volume
- 7
- Issue
- 5
- Pages
- 541-547
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1509868652
- Cited by
- 1,182
- References
- 66
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 20 · 2023: 21 · 2022: 33 · 2021: 55 · 2020: 29 · 2019: 29 · 2018: 28 · 2017: 30 · 2016: 36 · 2015: 51 · 2014: 50 · 2013: 60 · 2012: 60
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- major depressive disorder, neurobiology of depression, neuroplasticity, cell survival, signaling pathways
- MeSH terms
- Antidepressive Agents, Cell Survival, Depressive Disorder, Glucocorticoids, Neuronal Plasticity, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.